2013
DOI: 10.1684/ejd.2013.2169
|View full text |Cite
|
Sign up to set email alerts
|

Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm

Abstract: Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm Pimecrolimus 1% cream is an effective, non-corticosteroid, topical antiinflammatory treatment for atopic dermatitis (AD). The aim of this article was to review published clinical data that have examined how pimecrolimus can address the medical needs of AD patients. Clinical studies have demonstrated that early treatment with pimecrolimus decreases the progression to … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
21
0
23

Year Published

2014
2014
2021
2021

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 38 publications
(44 citation statements)
references
References 94 publications
0
21
0
23
Order By: Relevance
“…Long‐term use of topical steroids causes adverse effects, such as skin atrophy and infections, and there is a need to prevent inflammation in chronic inflammatory diseases, like AD . Heparinoid is known to have no serious side effects, probably because it cannot exert effects on an intact epidermis.…”
Section: Discussionmentioning
confidence: 99%
“…Long‐term use of topical steroids causes adverse effects, such as skin atrophy and infections, and there is a need to prevent inflammation in chronic inflammatory diseases, like AD . Heparinoid is known to have no serious side effects, probably because it cannot exert effects on an intact epidermis.…”
Section: Discussionmentioning
confidence: 99%
“…Guidelines universally recommend TCI for AD refractory to TCS, requiring chronic TCS, or involving sensitive skin. 15 A number of guidelines recommend both topical tacrolimus and pimecrolimus as second-line therapies, whereas Singaporean, German, and Polish guidelines recommend these medications as first line in areas prone to skin atrophy from TCS, termed "problem areas." 3,4,16 Compared to topical steroids, there is a lack of recommendations for TCI dose and frequency.…”
Section: Topical Calcineurin Inhibitorsmentioning
confidence: 99%
“…Pimekrolimus w postaci kremu 1% jest zalecany jako leczenie pierwszego rzutu w łagodnym AZS, a jego profil kliniczny sugeruje, że może być rozważany jako leczenie z wyboru w łagodnym i średnim AZS, zarówno u dzieci, jak i dorosłych, szczególnie we wrażliwych rejonach skóry [35].…”
Section: Miejscowe Inhibitory Kalcyneurynyunclassified
“…W przeciwieństwie do mGKS nie hamują one syntezy kolagenu, nie powodują ścieńczenia naskórka, rozszerzenia naczyń i nie uszkadzają bariery skórnej. Najczęstszym objawem niepożądanym związanym ze stosowaniem mIK jest pieczenie i zaczerwienienie skóry w miejscu aplikacji, które ustępuje po kilku dniach [14,35,36].…”
Section: Miejscowe Inhibitory Kalcyneurynyunclassified